FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1195 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with... April 30, 2026 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic... Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory... Licorice: The Unique Root With 10 Amazing Health Benefits
